MOR News and Press, MorphoSys AG From 10/27/22

The findings, including encouraging preliminary efficacy data in various tumor types, were presented during the 34th EORTC-NCI-AACR Symposium PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that preliminary results from th...

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner, GSK plc (GSK), provided an update on the ContRAst phase III program for otilimab as a potential treatment of moderate to severe rheumatoid arthritis (R...

The American Depository Receipts of MorphoSys AG ( NASDAQ: MOR ) dropped ~10% on Monday as both Deutsche Bank and Kempen downgraded the German biotech following weak sales data for the company’s cancer therapy Monjuvi. MorphoSys ( MOR ) has partnered with U....

MorphoSys ( NASDAQ: MOR ) is down -9.57% as of 1pm ET after Deutsche Bank downgraded the stock from a Hold to Sell. The downgrade comes a few days after the biopharmaceutical company lowered its FY22 outlook for cancer drug Monjuvi' U.S. net product sales citing "incre...

MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 Preliminary Q3 2022 Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million) Anticipated full year 2022 Monjuvi U.S. net product sales of approximately US$ 90 million...

MorphoSys AG (MOR) Q2 2022 Earnings Conference Call August 4, 2022 08:00 AM ET Company Participants Julia Neugebauer - IR Jean-Paul Kress - CEO Malte Peters - Chief Research & Development Officer Sung Lee - CFO Joseph Horvat - U.S. General Manager ...

Image source: The Motley Fool. MorphoSys AG (NASDAQ: MOR) Q2 2022 Earnings Call Aug 04, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: MorphoSys AG (MOR) Q2 2022 Earnings Call Transcript

MorphoSys press release ( NASDAQ: MOR ): 1H GAAP EPS of -€10.47. Revenue of €100.9M. For further details see: MorphoSys GAAP EPS of -€10.47, revenue of €100.9M

– Monjuvi ® U.S. net product sales of US$ 23.3 million (€ 21.7 million) for the second quarter 2022, a 25% Q-Q growth and 29% Y-Y growth – Efficacy and safety data of pelabresib for potential treatment improvement in myelofibrosis presented at EHA...

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 28, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) will publish its results for the second quarter and first half year 2022 results on August 3, 2022 at 10:00 pm CEST (9:00 pm BST; 4:00 pm EDT). MorphoSys' Management tea...